The Board of Directors has general responsibility for the Company’s governance and the appropriate organization of operations. The Board of Directors affirms the principles of the Company’s strategy, organization, accounting and controlling the management of assets, and appoints the CEO of the Company. The CEO is responsible for carrying out the strategy of the Company and for day-to-day administration based on the instructions and orders issued by the Board of Directors.
Dr. Adrian Harel
CEO, Founder of Medicortex, and Chairman of the Board
Board member since: 2014
Education: PhD Neurobiology, Weizmann Institute of Science, Israel. Post Doctorate, Washington University School of Medicine and Searle, St. Louis Missouri. MBA Business Administration, University of Haifa, Israel.
About: Dr. Harel has many years of experience in the pharmaceutical and biotech industry and extensive Drug R&D know-how as well as GMP production and manufacturing knowledge. He combines a broad scientific education with extensive industry experience. He has had several management positions, e.g., he was the CEO of ProNeuron where he was the head of a research division which had more than 20 scientists divided into three teams of research in different aspects including cell therapy, drug development and basic research. Additionally, in his last position, before Medicortex, he was the CEO of BrainStorm Cell Therapeutics (BCLI), a publicly-traded company in New York.
No. of shares in Medicortex/shareholding: 9 435 650
Independence: Dependent member
Dr. Mårten Kvist
Board member and Chairman of the Scientific and Clinical Advisory Board
Board member since: 2016
Education: MD, University of Helsinki, Finland. MD/PhD, University of Turku, Finland.
About: Dr. Kvist is an Associate Professor (Docent) in General Practice at the University of Turku and in Public Health at the University of Lapland. He has previously been a Team Leader for an International Project on Monitoring and Evaluation of the Health Reform in Egypt and done corresponding activities in Lesotho. As an Adviser for WHO, he has been running projects in 16 countries in the European region of WHO (EURO). Dr. Kvist has also been an adviser for three parliaments (Italy, Sweden and Finland) and many Ministries of Health in the European region. He has been successfully running projects related to the reconstruction of health care in post-war Bosnia and Herzegovina, and he has been in charge of the training of the staff in General Practice and Rehabilitation and for the reconstruction of rehabilitation centers (Banja Luka and Doboj). In cooperation with four universities in Russia (Moscow, Samara and two universities in St. Petersburg), he has developed the first Evidence-Based Medical Guidelines in Russian Federation in primary health care.
No. of shares in Medicortex/shareholding: 365 250
Independence: Dependent member
Independent board member
Board member since: 2021
Education: MSc, Uppsala University, Sweden. MBA, IMD Lausanne, Switzerland.
About: Anna Tenstam has over 30 years of leadership experience in pharmaceutical, medical devices and medical aesthetics companies worldwide. She has held executive positions in several global companies in these industries, as well as managed global brands and has been involved in several exits with companies such as Medicis, J&J, and Galderma. Tenstam built and managed global and local distribution networks via branches and distribution partners. She has served as Sr Advisor and fundraising executive for pharma and medical devices companies. Tenstam is the national project lead for Female Health Network and a member of Pokerface business network with entrepreneurs in Sweden. Lately she has been prioritizing a mentoring role to aspiring business people who are looking to enter the medical industry, and coaching young entrepreneurs in Sweden.
No. of shares in Medicortex/shareholding: 7000
Independence: Independent member